Symbols / IMRN $0.78 -3.33%
IMRN Chart
About
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 8.00M |
| Enterprise Value | 245.98M | Income | -4.65M | Sales | 7.48M |
| Book/sh | 0.03 | Cash/sh | 0.03 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -78.30 | PEG | — |
| P/S | 1.07 | P/B | 27.67 | P/C | — |
| EV/EBITDA | -51.90 | EV/Sales | 32.90 | Quick Ratio | 6.75 |
| Current Ratio | 8.04 | Debt/Eq | 1.56 | LT Debt/Eq | — |
| EPS (ttm) | -0.53 | EPS next Y | -0.01 | EPS Growth | — |
| Revenue Growth | 4.80% | Earnings | 2019-08-29 20:00 | ROA | -21.93% |
| ROE | -39.68% | ROIC | — | Gross Margin | 63.69% |
| Oper. Margin | -47.16% | Profit Margin | -62.14% | Shs Outstand | 8.17M |
| Shs Float | 322.66M | Short Float | 0.51% | Short Ratio | 1.25 |
| Short Interest | — | 52W High | 2.39 | 52W Low | 0.68 |
| Beta | 0.43 | Avg Volume | 47.11K | Volume | 5.75K |
| Target Price | $3.90 | Recom | Buy | Prev Close | $0.81 |
| Price | $0.78 | Change | -3.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.90
Mean price target
2. Current target
$0.78
Latest analyst target
3. DCF / Fair value
$-7.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.78
Low
$3.90
High
$3.90
Mean
$3.90
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-09-26 | init | Litchfield Hills | — → Buy | $5 |
| 2017-10-18 | init | HC Wainwright & Co. | — → Buy | $15 |
- $3.90 target: analyst backs Immuron after sales rise and cash boost - Stock Titan hu, 05 Mar 2026 08
- Immuron (IMRN) Struggles After Announcing Trial Results - Yahoo Finance Mon, 15 Dec 2025 08
- Immuron Limited (IMRN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Wed, 03 Dec 2025 08
- Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates - Stocktwits hu, 02 Oct 2025 07
- Immuron Limited (IMRN) Competitors - Meyka ue, 10 Mar 2026 00
- Immuron (NASDAQ: IMRN) adds U.S. DoD award as ETEC colostrum trial reports topline data next week - Stock Titan Wed, 03 Dec 2025 08
- Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales - Yahoo Finance ue, 30 Sep 2025 07
- IMRN Stock Faces Renewed Optimism Following Strategic Moves - StocksToTrade Wed, 03 Dec 2025 08
- Risk Analysis: Is IMRN stock a value trap - Weekly Trend Recap & Safe Entry Trade Reports - baoquankhu1.vn Sat, 07 Mar 2026 14
- Immuron (NASDAQ: IMRN) receives FDA IND approval; Phase 2 CDI trial planned first-half 2026 - Stock Titan Wed, 05 Nov 2025 08
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories! - TipRanks Wed, 10 Dec 2025 08
- Immuron’s Travelan diarrhea supplement lifts H1 sales to AUD$4.2M - Stock Titan Mon, 19 Jan 2026 08
- Aug PostEarnings: Is IMRN attractive for institutional investors - Share Buyback & Trade Opportunity Analysis - baoquankhu1.vn Sat, 07 Mar 2026 01
- IMMURON (IMRN) Stock Price, News & Analysis - MarketBeat Sun, 02 Jul 2017 01
- Pre-market Movers In Healthcare Sector: SELB, GNMK, IMRN, AGE, ACHV… - Nasdaq Fri, 09 Oct 2020 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -5.17M | -6.30M | -3.57M | -3.05M |
| TotalUnusualItems | 12.18K | -585.28K | -162.32K | 247.56K |
| TotalUnusualItemsExcludingGoodwill | 12.18K | -585.28K | -162.32K | 247.56K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -5.22M | -6.94M | -3.79M | -2.85M |
| ReconciledDepreciation | 49.69K | 45.98K | 48.66K | 42.61K |
| ReconciledCostOfRevenue | 2.52M | 1.57M | 495.56K | 241.69K |
| EBITDA | -5.16M | -6.88M | -3.73M | -2.81M |
| EBIT | -5.21M | -6.93M | -3.78M | -2.85M |
| NetInterestIncome | 128.56K | 320.18K | 106.67K | 15.60K |
| InterestExpense | 7.30K | 7.58K | 9.65K | 6.18K |
| InterestIncome | 135.87K | 327.76K | 116.32K | 21.79K |
| NormalizedIncome | -5.23M | -6.35M | -3.62M | -3.10M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -5.22M | -6.94M | -3.79M | -2.85M |
| TotalExpenses | 12.64M | 10.12M | 5.21M | 3.88M |
| RentExpenseSupplemental | 24.12K | 0.00 | 0.00 | 0.00 |
| TotalOperatingIncomeAsReported | -5.34M | -5.80M | -3.57M | -2.87M |
| DilutedAverageShares | 5.77M | 5.70M | 5.70M | 5.69M |
| BasicAverageShares | 5.77M | 5.70M | 5.70M | 5.69M |
| DilutedEPS | -0.90 | -1.22 | -0.66 | -0.50 |
| BasicEPS | -0.90 | -1.22 | -0.66 | -0.50 |
| DilutedNIAvailtoComStockholders | -5.22M | -6.94M | -3.79M | -2.85M |
| NetIncomeCommonStockholders | -5.22M | -6.94M | -3.79M | -2.85M |
| NetIncome | -5.22M | -6.94M | -3.79M | -2.85M |
| NetIncomeIncludingNoncontrollingInterests | -5.22M | -6.94M | -3.79M | -2.85M |
| NetIncomeContinuousOperations | -5.22M | -6.94M | -3.79M | -2.85M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -5.22M | -6.94M | -3.79M | -2.85M |
| OtherIncomeExpense | 12.18K | -2.04M | -486.66K | 247.56K |
| SpecialIncomeCharges | 0.00 | 0.00 | -2.38K | 0.00 |
| OtherSpecialCharges | -161.60K | |||
| WriteOff | 0.00 | 0.00 | 2.38K | 0.00 |
| EarningsFromEquityInterest | 0.00 | -1.46M | -324.34K | 0.00 |
| GainOnSaleOfSecurity | 12.18K | -585.28K | -159.94K | 247.56K |
| NetNonOperatingInterestIncomeExpense | 128.56K | 320.18K | 106.67K | 15.60K |
| InterestExpenseNonOperating | 7.30K | 7.58K | 9.65K | 6.18K |
| InterestIncomeNonOperating | 135.87K | 327.76K | 116.32K | 21.79K |
| OperatingIncome | -5.36M | -5.22M | -3.41M | -3.12M |
| OperatingExpense | 10.12M | 8.55M | 4.72M | 3.64M |
| OtherOperatingExpenses | -1.41M | -3.41M | -3.02M | -957.73K |
| OtherTaxes | -356.21K | |||
| ProvisionForDoubtfulAccounts | 19.23K | -11.69K | 19.11K | 8.81K |
| DepreciationAmortizationDepletionIncomeStatement | 49.69K | 45.98K | 48.66K | 42.61K |
| DepreciationAndAmortizationInIncomeStatement | 49.69K | 45.98K | 48.66K | 42.61K |
| DepreciationIncomeStatement | 49.69K | 45.98K | 48.66K | 42.61K |
| ResearchAndDevelopment | 3.60M | 5.38M | 2.59M | 657.72K |
| SellingGeneralAndAdministration | 7.87M | 6.55M | 5.08M | 3.89M |
| SellingAndMarketingExpense | 3.45M | 2.03M | 927.42K | 416.54K |
| GeneralAndAdministrativeExpense | 4.41M | 4.52M | 4.15M | 3.47M |
| OtherGandA | 1.45M | 1.66M | 1.47M | 1.70M |
| InsuranceAndClaims | 353.65K | 321.68K | 434.70K | 401.12K |
| RentAndLandingFees | 24.12K | 0.00 | 0.00 | 0.00 |
| SalariesAndWages | 2.61M | 2.54M | 2.24M | 1.37M |
| GrossProfit | 4.77M | 3.34M | 1.31M | 523.50K |
| CostOfRevenue | 2.52M | 1.57M | 495.56K | 241.69K |
| TotalRevenue | 7.29M | 4.90M | 1.80M | 765.19K |
| OperatingRevenue | 7.29M | 4.90M | 1.80M | 765.19K |
| Line Item | 2024-06-30 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 233.96M | 228.00M | 227.80M | 227.80M |
| ShareIssued | 233.96M | 228.00M | 227.80M | 227.80M |
| TotalDebt | 71.86K | 132.94K | 189.09K | 209.79K |
| TangibleBookValue | 8.07M | 12.71M | 19.62M | 23.18M |
| InvestedCapital | 8.07M | 12.71M | 19.62M | 23.18M |
| WorkingCapital | 8.05M | 12.03M | 18.19M | 22.17M |
| NetTangibleAssets | 8.07M | 12.71M | 19.62M | 23.18M |
| CapitalLeaseObligations | 71.86K | 132.94K | 189.09K | 209.79K |
| CommonStockEquity | 8.07M | 12.71M | 19.62M | 23.18M |
| TotalCapitalization | 8.07M | 12.71M | 19.62M | 23.18M |
| TotalEquityGrossMinorityInterest | 8.07M | 12.71M | 19.62M | 23.18M |
| StockholdersEquity | 8.07M | 12.71M | 19.62M | 23.18M |
| GainsLossesNotAffectingRetainedEarnings | 1.64M | 3.17M | 3.24M | 3.17M |
| RetainedEarnings | -82.44M | -78.97M | -72.06M | -68.43M |
| CapitalStock | 88.87M | 88.50M | 88.44M | 88.44M |
| CommonStock | 88.87M | 88.50M | 88.44M | 88.44M |
| TotalLiabilitiesNetMinorityInterest | 2.06M | 2.84M | 2.37M | 1.68M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 94.58K | 141.55K | 152.21K | 175.45K |
| EmployeeBenefits | 22.72K | 8.61K | 1.88K | 36.00 |
| LongTermDebtAndCapitalLeaseObligation | 71.86K | 132.94K | 150.32K | 175.41K |
| LongTermCapitalLeaseObligation | 71.86K | 132.94K | 150.32K | 175.41K |
| CurrentLiabilities | 1.97M | 2.70M | 2.22M | 1.50M |
| OtherCurrentLiabilities | 45.27K | 40.56K | 34.38K | 20.50K |
| CurrentDeferredLiabilities | 0.00 | 698.20K | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 698.20K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 40.56K | 38.77K | 34.38K | 20.50K |
| CurrentCapitalLeaseObligation | 40.56K | 38.77K | 34.38K | 20.50K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 391.50K | 522.57K | 289.41K | 211.78K |
| CurrentProvisions | 95.93K | 213.02K | ||
| PayablesAndAccruedExpenses | 1.53M | 2.14M | 1.19M | 1.16M |
| CurrentAccruedExpenses | 492.85K | 1.45M | 394.03K | 411.91K |
| Payables | 1.04M | 690.40K | 798.74K | 748.98K |
| OtherPayable | 29.92K | 41.55K | 7.82K | 28.11K |
| AccountsPayable | 1.01M | 648.85K | 790.92K | 720.87K |
| TotalAssets | 10.13M | 15.55M | 21.99M | 24.86M |
| TotalNonCurrentAssets | 114.62K | 823.63K | 1.58M | 1.18M |
| OtherNonCurrentAssets | 666.00 | 669.28K | 1.22M | 956.94K |
| InvestmentsAndAdvances | 0.00 | 159.07K | 0.00 | |
| LongTermEquityInvestment | 0.00 | 159.07K | 0.00 | |
| NetPPE | 113.95K | 154.35K | 200.13K | 226.74K |
| AccumulatedDepreciation | -496.84K | -450.86K | -402.19K | |
| GrossPPE | 651.18K | 650.99K | 628.93K | |
| Leases | 243.35K | 243.35K | 229.03K | |
| OtherProperties | 243.35K | 229.03K | ||
| MachineryFurnitureEquipment | 407.83K | 407.64K | 399.90K | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 10.02M | 14.73M | 20.41M | 23.67M |
| OtherCurrentAssets | 7.67K | 10.04K | 78.26K | |
| PrepaidAssets | 3.48M | 86.80K | 158.15K | 572.40K |
| Inventory | 1.77M | 1.58M | 839.97K | 326.58K |
| OtherInventories | 35.00 | 150.99K | 682.00 | 37.00 |
| FinishedGoods | 1.14M | 610.02K | 394.38K | 64.92K |
| WorkInProcess | 433.05K | 683.85K | 444.90K | 124.41K |
| RawMaterials | 199.23K | 139.75K | 0.00 | 137.21K |
| Receivables | 1.93M | 1.39M | 417.42K | 662.90K |
| OtherReceivables | 1.13M | 796.37K | 398.39K | 454.55K |
| AccountsReceivable | 791.39K | 591.20K | 19.03K | 208.34K |
| AllowanceForDoubtfulAccountsReceivable | -35.47K | -16.23K | -27.92K | -8.81K |
| GrossAccountsReceivable | 826.86K | 607.44K | 46.95K | 217.15K |
| CashCashEquivalentsAndShortTermInvestments | 2.83M | 11.66M | 18.99M | 22.11M |
| OtherShortTermInvestments | 0.00 | 1.83M | 0.00 | |
| CashAndCashEquivalents | 2.83M | 11.66M | 17.16M | 22.11M |
| CashFinancial | 2.83M | 11.66M | 17.16M | 22.11M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -6.14M | -5.88M | -2.60M | -3.16M |
| RepaymentOfDebt | -65.66K | -15.60K | -35.02K | -36.26K |
| IssuanceOfDebt | 0.00 | 0.00 | 212.79K | |
| IssuanceOfCapitalStock | 396.83K | 24.00K | 0.00 | 0.00 |
| CapitalExpenditure | -195.00 | -7.74K | -10.05K | -6.63K |
| EndCashPosition | 2.83M | 11.66M | 17.16M | 22.11M |
| BeginningCashPosition | 11.66M | 17.16M | 22.11M | 25.05M |
| EffectOfExchangeRateChanges | 10.82K | 49.30K | 310.63K | 241.50K |
| ChangesInCash | -8.84M | -5.55M | -5.26M | -3.18M |
| FinancingCashFlow | 199.75K | 829.00 | -44.67K | -42.45K |
| CashFlowFromContinuingFinancingActivities | 199.75K | 829.00 | -44.67K | -42.45K |
| NetOtherFinancingCharges | -124.11K | -2.75M | ||
| InterestPaidCFF | -7.30K | -7.58K | -9.65K | -6.18K |
| CashDividendsPaid | 0.00 | 0.00 | 0.00 | 0.00 |
| NetCommonStockIssuance | 396.83K | 24.00K | 0.00 | 0.00 |
| CommonStockIssuance | 396.83K | 24.00K | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | -65.66K | -15.60K | -35.02K | -36.26K |
| NetLongTermDebtIssuance | -65.66K | -15.60K | -35.02K | -36.26K |
| LongTermDebtPayments | -65.66K | -15.60K | -35.02K | -36.26K |
| LongTermDebtIssuance | 0.00 | 0.00 | 212.79K | |
| InvestingCashFlow | -2.90M | 327.56K | -2.62M | 11.74K |
| CashFlowFromContinuingInvestingActivities | -2.90M | 327.56K | -2.62M | 11.74K |
| InterestReceivedCFI | 135.87K | 327.76K | 116.32K | 21.79K |
| NetInvestmentPurchaseAndSale | -3.04M | 0.00 | 0.00 | |
| PurchaseOfInvestment | -3.04M | 0.00 | 0.00 | |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -2.73M | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | -2.73M | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | -195.00 | -7.74K | -10.05K |
| PurchaseOfPPE | 0.00 | -195.00 | -7.74K | -10.05K |
| CashFlowsfromusedinOperatingActivitiesDirect | -6.14M | -5.88M | -2.60M | -3.15M |
| TaxesRefundPaidDirect | 768.43K | 395.00K | 251.99K | 306.15K |
| ClassesofCashPayments | -14.77M | -12.91M | -7.84M | -4.63M |
| PaymentstoSuppliersforGoodsandServices | -14.77M | -12.91M | -7.84M | -4.63M |
| ClassesofCashReceiptsfromOperatingActivities | 8.64M | 7.03M | 5.25M | 1.48M |
| OtherCashReceiptsfromOperatingActivities | 358.28K | |||
| ReceiptsfromGovernmentGrants | 274.73K | 1.90M | 3.08M | 478.59K |
| ReceiptsfromCustomers | 7.59M | 4.73M | 1.91M | 696.60K |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for IMRN
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|